Group 1 - The author has over 15 years of experience in investing and has provided research services to mid-sized hedge funds with assets under management between $100 million and $500 million [1] - The investment strategy focuses on medium-term investing in ideas with catalysts to unlock value or short selling in case of downside catalysts [1] - The author has a generalist approach but has higher conviction in the industrial, consumer, and technology sectors due to extensive professional experience analyzing these areas [1] Group 2 - The author has no current stock, option, or similar derivative positions in the companies mentioned but may initiate a long position in TMO and DHR within the next 72 hours [2] - The article expresses the author's own opinions and is not receiving compensation from any company mentioned [2] - Seeking Alpha emphasizes that past performance is not indicative of future results and that the views expressed may not reflect those of the platform as a whole [3]

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $10.6 billion, with adjusted operating income of $2.36 billion and an adjusted operating margin of 22.3% [5][21] - Adjusted EPS for the quarter was $5.28, allowing the company to raise its adjusted EPS guidance for the year to a range of $21.35 to $22.07 [20][22] - Year-to-date free cash flow was $4.5 billion, with a free cash flow from operations of $5.4 billion, reflecting a 22% increase compared to the same period last year [22][26] Performance by Business Segment - Life Sciences Solutions segment reported a 2% decline in revenue, with organic revenue down 4% year-over-year, primarily due to pandemic-related impacts [26] - Analytical Instruments segment saw both reported and organic revenue grow by 3%, driven by strong performance in the electron microscopy business [27] - Specialty Diagnostics segment experienced a 4% growth in both reported and organic revenue, led by healthcare market channels and immunodiagnostics [28] - Laboratory Products and Biopharma Services segment's revenue was flat year-over-year, with mid-single-digit impacts from the runoff of vaccines and therapies [29] Market Data and Key Metrics Changes - North America experienced a low-single-digit decline, while Europe, Asia-Pacific, and China were flat year-over-year [23] - The diagnostics and healthcare market growth was flat, impacted by the runoff of COVID-19 testing-related revenue [7][23] Company Strategy and Development Direction - The company's growth strategy focuses on high-impact innovation, trusted partner status with customers, and a strong commercial engine [8][12] - Recent innovations include the launch of the Thermo Scientific Iliad scanning transmission electron microscope and the Applied Biosystems MagMAX Sequential DNA/RNA kit [10][11] - The company is expanding its capabilities in response to customer needs, including new bioanalytical labs and enhanced manufacturing footprints [14] Management's Comments on Operating Environment and Future Outlook - Management noted a gradual recovery in market conditions, with expectations for organic growth to return in Q4 2024 [35][36] - The company anticipates that the runoff of pandemic-related activity will continue to be a headwind but expects less impact in 2025 [36][37] - Management expressed confidence in the long-term health of the pharma and biotech sectors, citing improved funding and customer confidence [39] Other Important Information - The company has a disciplined capital deployment strategy, with $3.1 billion allocated for the acquisition of Olink and plans for share buybacks [18][31] - Corporate social responsibility initiatives are integrated into the company's strategy, focusing on environmental impact and community support [16] Q&A Session Summary Question: Expectations for market recovery into 2025 - Management indicated that market conditions are gradually improving, with expectations for continued organic growth into 2025, although the pace of recovery may be slow [34][36] Question: Performance of pharma and biotech segments - The company noted a low-single-digit decline in the pharma and biotech segment, with a significant headwind from the runoff of pandemic-related revenues, but overall conditions are improving [38][39] Question: Update on clinical research business and customer trends - The clinical research business is performing well, with a larger share of biotech customers adopting unified capabilities, leading to positive momentum [41][42] Question: Life Sciences Solutions segment performance - The Life Sciences Solutions segment's performance was in line with expectations, with the most significant impact from COVID-related activities occurring in Q3 [43][44] Question: Overall portfolio performance and geographic trends - The portfolio is tracking as planned, with biotech funding improving and muted economic activity in China impacting growth expectations [55][56]

For the quarter ended September 2024, Thermo Fisher Scientific (TMO) reported revenue of $10.6 billion, up 0.2% over the same period last year. EPS came in at $5.28, compared to $5.69 in the year-ago quarter.The reported revenue represents a surprise of -0.42% over the Zacks Consensus Estimate of $10.64 billion. With the consensus EPS estimate being $5.25, the EPS surprise was +0.57%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

Thermo Fisher Scientific Inc.'s (TMO) third-quarter 2024 adjusted earnings per share (EPS) of $5.28 beat the Zacks Consensus Estimate by 0.6%. However, the figure decreased 7.2% year over year.The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs.GAAP EPS was $4.25, down 3.8% on a year-over-year basis.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, shares of TMO decreased nearly 2% in the ...

For Thermo Fisher Scientific Inc. (NYSE: TMO ), I highlighted the downturn in the pharma and biotech industry as well as weak growth in China in my previous article published in January 2024. I anticipate the overall pharmaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of TMO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no b ...

Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Lab Consumables - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Lab Consumables is estimated at US$12.7 Million in 2023 and is projected to reach US$17.2 Million by 2030, growing at a CAGR of 4.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The manufacturing and supply of l ...

Core Viewpoint - Thermo Fisher Scientific (TMO) is expected to report a quarterly earnings per share (EPS) of $5.25, reflecting a 7.7% decline year-over-year, while revenues are forecasted to increase by 0.7% to $10.64 billion [1] Revenue Estimates - Analysts project 'Revenues- Laboratory Products and Biopharma Services' to be $5.67 billion, indicating a year-over-year decrease of 1% [2] - The estimated 'Revenues- Specialty Diagnostics' is $1.10 billion, reflecting a year-over-year increase of 1.3% [2] - 'Revenues- Life Sciences Solutions' is expected to reach $2.47 billion, showing a year-over-year increase of 1.7% [2] Geographic Revenue Estimates - 'Revenues- Analytical Instruments' is projected to be $1.85 billion, indicating a year-over-year increase of 5.5% [3] - 'Geographic Revenues- Customer Location- North America' is expected to be $5.64 billion, reflecting a decrease of 0.4% from the prior year [3] - 'Geographic Revenues- Customer Location- Asia-Pacific' is forecasted at $1.94 billion, indicating a year-over-year increase of 1.4% [3] - 'Geographic Revenues- Customer Location- Other regions' is estimated to reach $359.04 million, reflecting a year-over-year increase of 2.6% [3] - 'Geographic Revenues- Customer Location- Europe' is projected to be $2.70 billion, indicating a year-over-year increase of 2.2% [3] Stock Performance - Shares of Thermo Fisher have shown a return of -3.4% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3.8% [3]

The market expects Thermo Fisher Scientific (TMO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on October 23, 2024, might help the stock move higher if these ...

Core Viewpoint - Thermo Fisher Scientific Inc. is expected to report its third-quarter 2024 results on October 23, with mixed expectations for revenue and earnings performance compared to the previous year [1][2]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for Thermo Fisher's Q3 revenues is $10.64 billion, reflecting a 0.6% increase from the same quarter last year [2]. - The consensus estimate for earnings is $5.25 per share, indicating a 7.7% decline from the year-ago quarter [2]. - Earnings estimates have decreased by 0.6% in the past 30 days [3]. Group 2: Segment Performance Insights - The Analytical Instruments segment is anticipated to show strong sales growth, with projected revenues of $1.9 billion, representing a 12.7% year-over-year increase, driven by new product launches [5]. - The Life-Science Solutions segment is expected to generate $2.5 billion in revenues, marking a 2% improvement year over year, aided by the acquisition of Olink Holding AB [8]. - The Specialty Diagnostics segment is projected to report $1 billion in revenues, suggesting a 3.1% decline year over year, despite positive contributions from transplant diagnostics and immunodiagnostics [11]. Group 3: Recent Developments and Innovations - The company launched several new products, including the Thermo Scientific Stellar Mass Spectrometer and new editions of the ThermoScientific Orbitrap Ascend Tribrid Mass Spectrometer, which are expected to enhance revenue [4][5]. - A new bio-based film for single-use technologies was introduced, contributing to growth in the bioproduction business [7]. - Recent partnerships and product launches, such as the CorEvitas Adolescent Atopic Dermatitis Registry and the myeloMATCH trial with the National Cancer Institute, are expected to positively impact the company's performance [9][10]. Group 4: Operational Expansion - Thermo Fisher opened a new electron microscopy demo center in Taiwan and expanded its global laboratory services with a new bioanalytical lab in Sweden, which may favorably influence revenue [12][13].

Thermo Fisher Scientific Inc. (TMO) is making robust progress with its growth strategy, which bodes well for the upcoming quarters. The spree of innovative product introductions bolsters its portfolio. The company's Bioproduction business is expanding and increasing its capacity to meet the rising demand. Meanwhile, the adverse macroeconomic impacts and currency fluctuations raise concerns for TMO's operations, In the past year, shares of this Zacks Rank #3 (Hold) company have rallied 20.7% compared with th ...